Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis Genovese, M. C., Fleischmann, R. M., Jasson, M., Radin, A. R., Hamilton, J., Huizinga, T. J. WILEY-BLACKWELL. 2012: S568
View details for Web of Science ID 000309748303041